Café

MPLT

13.8657.69%( -1.155 )

LongbridgeAI

MPLT

13.8657.69%( -1.155 )

MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.

benzinga_article

Jun 22, 2026 at 10:44 AM

MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

MapLight Therapeutics

MPLT.US

Open

High

Low

Prev Close

P/E^TTM

Market Cap

LongbridgeAI

MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.

benzinga_article

Jun 22, 2026 at 10:44 AM

MapLight Therapeutics shares are trading higher after the company announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

MapLight Therapeutics

MPLT.US

Open

High

Low

Prev Close

P/E^TTM

Market Cap